Wechselwirkungen · Repaglinide Teva
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-210739 · Präparat HOS-154579
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-11T17:40:00Z · SHA-256 7ea88aaeb62655814b4cbb82e87f581c1d76d8e897c814045f52ed8ce0706612 · Passage b3d5c7185030d7330d3356f73c3bf7ab48d2a6b40884d39bc9df8c7da53c6b16 · Zeichen 2076–2815 im Abschnitt